Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xiaflex Risk/Benefit Profile Acceptable Despite Tendon Ruptures, Auxilium Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III data supports Xiaflex injection as alternative to surgery for treating Dupuytren’s contracture.

You may also be interested in...



Auxilium Submits Xiaflex BLA, Scans Wide-Open Orphan Market

Niche indications in Dupuytren’s and Peyronie’s could pay off for Auxilium and partner Pfizer.

Auxilium Submits Xiaflex BLA, Scans Wide-Open Orphan Market

Niche indications in Dupuytren’s and Peyronie’s could pay off for Auxilium and partner Pfizer.

Pfizer And Auxilium Set Partnership For European Rights To Xiaflex

For $75 million upfront plus milestones and royalties, Pfizer gets Xiaflex rights for two indications in 46 countries.

Topics

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel